echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: berzosertib + gemcitabine + cisplatin combined treatment of advanced solid tumors

    Br J Cancer: berzosertib + gemcitabine + cisplatin combined treatment of advanced solid tumors

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chemotherapy drugs, including platinum drugs and gemcitabine, induce a potentially fatal DNA damage response (DDR) in cancer cells, which is part of the standard treatment for many cancers
    .
    However, chemotherapeutic drug resistance can lead to poorer clinical outcomes in patients
    .
    One mechanism associated with inherent and acquired resistance is through the activation of complex DNA damage repair mechanisms

    .

    Chemotherapy drugs, including platinum drugs and gemcitabine, induce a potentially fatal DNA damage response (DDR) in cancer cells, which is part of the standard treatment for many cancers
    .
    Chemotherapy drugs, including platinum drugs and gemcitabine, induce a potentially fatal DNA damage response (DDR) in cancer cells, which is part of the standard treatment for many cancers
    .

    DDR top adjustment factor is ATM (ataxia capillary blood vessel dilation mutated kinases), and the ATR (ataxia telangiectasia and Rad3 related protein kinase), ATR reaction is mainly single exposure stranded DNA, as these are usually single stranded DNA Produced by DNA damage and replication stress, ATM corresponds to DNA double-strand breaks
    .

    Blood vessel


    Previous studies have shown that inhibition of ATR is a potential cancer treatment target.
    In these cancers, DNA damaging chemotherapy has been used as a standard treatment, but further research is still needed

    .


    Berzosertib (M6620, VX-970) is a highly effective and selective ATR inhibitor
    .
    This study aims to evaluate the efficacy of multiple escalating doses of berzosertib + gemcitabine + cisplatin in patients with drug-resistant/refractory advanced solid tumors
    .

    Berzosertib (M6620, VX-970) is a highly effective and selective ATR inhibitor
    .
    Berzosertib (M6620, VX-970) is a highly effective and selective ATR inhibitor
    .


    The researchers used a standard 3+3 dose escalation treatment strategy to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of intravenous berzosertib + gemcitabine + cisplatin combination therapy
    .
    The starting dose of treatment is berzosertib 18 mg/m 2 , gemcitabine 875 mg/m 2 and cisplatin 60 mg/m 2
    .


    The researchers used a standard 3+3 dose escalation treatment strategy to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of intravenous berzosertib + gemcitabine + cisplatin combination therapy
    .
    The researchers used a standard 3+3 dose escalation treatment strategy to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of intravenous berzosertib + gemcitabine + cisplatin combination therapy
    .
    2 2 2

    Related research design drawings

    Related research design drawings

    The results showed that a total of 52 patients received berzosertib + gemcitabine treatment, while the other eight patients received berzosertib + gemcitabine + cisplatin combination therapy
    .
    The researchers found that four patients treated with berzosertib + gemcitabine had a total of seven dose-limiting toxicities (DLT), while the berzosertib + gemcitabine + cisplatin treatment group had a total of three DLTs

    .


    The researchers determined that the recommended dose for Phase 2 (RP2D) was: berzosertib 210mg/m 2 (days 2 and 9) + gemcitabine 1000mg/m 2 (days 1 and 8); they did not determine berzosertib+ gemcitabine + cis RP2D with platinum combination therapy
    .
    Further studies have shown that neither gemcitabine nor cisplatin will affect the pharmacokinetics of berzosertib
    .
    And most patients have achieved the best partial remission or stable disease

    .


    The researchers determined that the recommended dose for Phase 2 (RP2D) was: berzosertib 210mg/m 2 (days 2 and 9) + gemcitabine 1000mg/m 2 (days 1 and 8); they did not determine berzosertib+ gemcitabine + cis RP2D with platinum combination therapy
    .
    The researchers determined that the recommended dose for Phase 2 (RP2D) was: berzosertib 210mg/m 2 (days 2 and 9) + gemcitabine 1000mg/m 2 (days 1 and 8); they did not determine berzosertib+ gemcitabine + cis RP2D with platinum combination therapy
    .
    2 2

    Berzosertib plasma concentration-time curve

    Berzosertib plasma concentration-time curve

    All in all, the results of the study revealed that patients with advanced solid tumors tolerated the berzosertib+gemcitabine combination therapy well and showed preliminary efficacy
    .

    Patients with advanced solid tumors tolerated berzosertib+gemcitabine combination therapy well and showed preliminary efficacy
    .
    Patients with advanced solid tumors tolerated berzosertib+gemcitabine combination therapy well and showed preliminary efficacy
    .


    Original source:


    Middleton, MR, Dean, E.
    , Evans, TRJ et al.
    Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
    Br J Cancer (26 May 2021 ).

    Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.